Yes, prostate biopsies can be wrong, with significant rates of false negatives (missing cancer), often 20-30% or more, because they sample a tiny part of the gland, and cancer cells might be missed. False positives (diagnosing cancer when it's not there) can also occur, though less commonly, due to lab errors or benign conditions mimicking cancer. Newer techniques, like MRI-targeted biopsies, aim to improve accuracy.
Unfortunately, prostate biopsy has a 30-40% false negative rate, requiring many men to undergo the procedure again. The patient suffers fear and stress in the meantime.
If your doctor finds an abnormality during a DRE or MRI, or if PSA testing detects a raised PSA level, you may need a biopsy. A prostate biopsy is one of the most accurate ways to diagnose prostate cancer. But biopsy can still miss 1 in 5 prostate cancersThis link is external and opens in a new tab.
Although tests aren't 100% accurate all the time, receiving a wrong answer from a cancer biopsy – called a false positive or a false negative – can be especially distressing. While data are limited, an incorrect biopsy result generally is thought to occur in 1 to 2% of surgical pathology cases.
A man who undergoes transrectal biopsy has a 1-in-4 chance of being diagnosed with prostate cancer – most of these cancers tend to be the indolent type that men die with and not from. Transrectal biopsies can miss clinically significant cancers.
In summary, systematic biopsies have a limited role in prostate cancer diagnosis. The cancer that is typically identified by systematic biopsies is not of the nature that is likely to benefit from treatment but can lead to expensive monitoring strategies and harmful patient side effects if overtreated.
A prostate biopsy can result in such complications as: hematuria, rectal bleeding, pain in hypogastrium, perineum or urethra, fever, nausea, vomiting, retention of urine or other adverse events.
THE '2-week rule' represents a significant organisational change in the referral of patients with suspected cancer. Targets set by the rule include that secondary care specialists should be notified within 24 hours and see patients within 2 weeks from when the general practitioner (GP) decides to refer a patient.
Existing estimates of the incidence rates suggest that 10–15 percent of diagnoses are not entirely correct,” and Cordula Wagner (Executive Director, Professor of Patient Safety, Netherlands Institute for Health Services Research, Utrecht) reminds us that diagnostic errors have a severe impact – “There may be more ...
An accurate diagnosis is essential to ensure that the correct and most effective treatment is given. Getting a second opinion on a diagnosis can reverse a diagnosis or alter the treatment plan.
Increased PSA and/or abnormal DRE is the most frequent finding prompting prostate biopsy. At initial biopsy 20% to 30% of patients are diagnosed with prostate cancer and the rest are followed clinically and possibly undergo repeat biopsies.
Risks associated with a prostate biopsy include: Bleeding at the biopsy site. Rectal bleeding is common after a prostate biopsy. Blood in your semen.
The authors concluded that 9.9% of all the cancers, most of which were clinically significant, were not diagnosed, even though 20-core biopsies were taken. In this study, the false negative rate of 12-core prostate biopsy technique was found to be more than 30%.
The short answer to this question is that it's extremely rare for cancer to spread during a biopsy. The benefits of getting a biopsy far outweigh the minimal risk of cancer spread.
Needle biopsies take a smaller tissue sample and may miss the cancer. However, even with needle biopsies, false negative results are not common. One study looking at nearly 1,000 core needle biopsies found a false negative result rate of 2.2%.
Cancers, infections, and cardiovascular events (the “Big 3”) account for 75% of all serious harm from diagnostic mistakes. There are over 10,000 diseases and many of them present overlapping symptoms. Diagnostic error rates range from 5% in outpatient settings to 6–17% in hospitals.
A 2023 study by the British Medical Journal (BMJ) estimated that misdiagnoses affect around 1 in 18 patients in primary and secondary care. The same study found that misdiagnosed cancers, strokes, and heart attacks were among the most serious cases, often leading to life-altering consequences or death.
The role of a pathologist is to look for signs of abnormalities and unusual cell growth in patient biopsy samples. However, if they misread the results, it can lead to an error in the diagnosis.
Your biopsy samples will be sent to a lab, where a doctor with special training, called a pathologist, will look at them with a microscope to see if they contain cancer cells. Getting the results (in the form of a pathology report) usually takes 1 to 3 days, but it can sometimes take longer.
Providers may recommend biopsies to diagnose or monitor medical conditions or to plan treatment. You may hear the term “biopsy” and think “cancer,” but providers do biopsies to diagnose many medical conditions, like: Inflammatory disorders, such as in your kidney (nephritis) or liver (hepatitis).
Some experts have recommended that a repeat biopsy be done no sooner than 3 months after the initial biopsy, since the damage and repair to cells in the area of the biopsy could cause the biopsy result to be wrongly interpreted as cancer.
It is widely acknowledged that Transrectal Ultrasound (TRUS) guided biopsy of the prostate is not 100% sensitive and that cases of prostate cancer can be missed. Many research groups have tried to quantify the false negative biopsy rate, with most reporting a figure of between 20% and 30% [1], [2], [3], [4].
Biopsy currently remains the gold standard of prostate cancer diagnosis. Although imaging with multiparametric magnetic resonance imaging (mpMRI) has the potential to increase detection and localisation of prostate cancer, tissue is still required for histological confirmation.
The decision to investigate further with a prostate biopsy is based on a combination of factors, including results of the PSA, DRE and other tests, family history, age, race and other medical conditions you may have. A biopsy should be performed only after discussing the procedure's risks and benefits with your doctor.